Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPELA: Capecitabine + Elacestrant in Advanced ER+ Breast Cancer
NCT07222215Phase 2Recruiting
- Start
- Jan 2026
- Primary completion
- Dec 2029
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
A Phase 2 trial of elacestrant in breast cancer. Started Jan 2026; status: recruiting.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07222215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07222215.